Clostridioides difficile Infection - Severity Assessment and Treatment

Key Points

• Test only patients with a compatible clinical syndrome, not formed stool or asymptomatic colonization.
• NAAT positivity can reflect colonization, so interpret results with symptoms and local testing algorithms.
• Fidaxomicin is preferred for many nonfulminant initial and recurrent episodes when available.
• Oral vancomycin remains an acceptable initial treatment alternative.
• Do not use routine test-of-cure after clinical recovery.
• Fulminant CDI requires enteral vancomycin plus IV metronidazole and early surgical involvement.
• Ileus can require rectal vancomycin because oral drug may not reach the distal colon adequately.
• Multiple recurrences may benefit from microbiota-based therapy.

Algorithm

1. Confirm clinically significant new diarrhea or ileus and remove noninfectious explanations when possible.
2. Send testing according to the local multistep or NAAT-based algorithm.
3. Stop unnecessary inciting antibiotics and review infection-control precautions.
4. Classify nonsevere, severe, or fulminant disease using labs and bedside physiology.
5. For nonfulminant CDI, use fidaxomicin or oral vancomycin according to guideline and access.
6. For recurrence, review prior regimen and consider fidaxomicin, vancomycin taper, bezlotoxumab, or microbiota-based therapy.
7. For fulminant disease, give high-dose enteral vancomycin plus IV metronidazole and add rectal vancomycin with ileus.
8. Escalate to surgery early for shock, megacolon, perforation, or worsening organ failure.

Clinical Synopsis & Reasoning

C. difficile infection should be considered in patients with new unexplained diarrhea, especially after antibiotic exposure, hospitalization, long-term care exposure, advanced age, immunosuppression, or prior CDI. Testing asymptomatic patients or patients with formed stool identifies colonization and leads to overtreatment. A typical testing threshold is three or more unformed stools in 24 hours when laxatives or another obvious cause do not explain the symptoms.

Laboratory algorithms vary. Nucleic acid amplification is highly sensitive for toxigenic organisms but can detect colonization, so many institutions combine glutamate dehydrogenase, toxin enzyme immunoassay, and NAAT in multistep strategies. Interpret every positive result in the clinical context. Leukocytosis and creatinine help stratify severity but do not replace bedside assessment. Severe abdominal pain, distention, ileus, toxic megacolon, hypotension, shock, lactate elevation, or organ failure raise concern for fulminant disease.

Stop the inciting antibiotic when clinically possible and review proton-pump inhibitor or other modifiable exposures without discontinuing necessary therapy. Use contact precautions and soap-and-water hand hygiene in outbreak or clinical settings according to infection-control policy because spores resist routine alcohol hand rub. Do not perform routine test-of-cure after symptoms resolve because stool assays can remain positive.

Treatment Strategy & Disposition

For an initial nonfulminant episode, the 2021 IDSA/SHEA focused update suggests fidaxomicin over a standard vancomycin course when resources allow, while oral vancomycin remains an acceptable alternative. Fidaxomicin reduces recurrence because it has a narrower microbiome effect. Metronidazole is no longer preferred first-line therapy when fidaxomicin or vancomycin is available.

Recurrent CDI requires attention to episode number and prior therapy. Fidaxomicin, including extended-pulsed regimens, is preferred for many recurrences; a vancomycin taper and pulse is an accepted alternative, particularly after a first recurrence. Bezlotoxumab can reduce recurrence in selected high-risk patients when available, though heart-failure risk and logistics matter. Multiple recurrences may be treated with fecal microbiota-based therapy after appropriate antibiotic treatment under current regulatory and institutional protocols.

Fulminant CDI is a different emergency. Give oral or nasogastric vancomycin at fulminant dosing and IV metronidazole; add rectal vancomycin when ileus prevents adequate colonic delivery. Provide aggressive fluid and electrolyte resuscitation, stop antimotility drugs, obtain early surgery consultation, and monitor lactate, abdominal examination, and organ function. Subtotal colectomy or diverting-loop strategies may be lifesaving when shock, megacolon, perforation, or progressive organ failure develops despite medical therapy.

Epidemiology / Risk Factors

• Antibiotic exposure is the major modifiable risk factor for CDI.
• Older adults and hospitalized or long-term-care patients have increased incidence and recurrence.
• Community-associated cases occur and can lack recent hospitalization.
• Recurrent disease is common because antibiotics do not fully restore colonization resistance.

Investigations

Severity Concepts

Pharmacology

Prognosis / Complications

• Most nonfulminant episodes respond to appropriate therapy.
• Recurrence occurs in a meaningful fraction after initial treatment and risk rises with each episode.
• Fulminant colitis can progress quickly to shock, megacolon, perforation, and death.
• Early surgical involvement improves readiness for patients who fail medical therapy.

Patient Education / Counseling

• Complete the prescribed CDI regimen even when diarrhea improves early unless a clinician changes it.
• Do not take leftover antibiotics or antidiarrheal drugs without advice.
• Wash hands with soap and water after toileting and before food preparation during active infection.
• Return urgently for severe abdominal pain, distention, fainting, inability to drink, or reduced urine output.
• Tell future clinicians about prior CDI so unnecessary broad-spectrum antibiotics can be avoided.

Notes

C. difficile testing is one of the clearest examples of why laboratory sensitivity cannot replace clinical selection. A highly sensitive NAAT performed on a patient whose diarrhea is caused by laxatives may identify colonization and expose the patient to unnecessary treatment.

The 2021 focused guideline changed the balance toward fidaxomicin because of lower recurrence, but access and cost remain real constraints. Oral vancomycin therefore remains a guideline-supported alternative rather than an obsolete treatment.

References

1. SHEA/IDSA 2021 Focused Update for Clostridioides difficile Infection — Link
2. IDSA Clinical Practice Guideline for Clostridium difficile Infection — Link